Advanced non-small-cell lung cancer: how to manage EGFR and HER2 exon 20 insertion mutation-positive disease

Advanced non-small-cell lung cancer: how to manage EGFR and HER2 exon 20 insertion mutation-positive disease

EGFR exon 20 insertion mutations (Ex20ins) and HER2 mutations characterize an oncogene-addicted subtype of non-small-cell lung cancer (NSCLC) typically associated with a never or light smoking history, female sex, and adenocarcinoma histology. Nevertheless, Ex20ins-mutant and HER2-mutant advanced NS...

Full description

Bibliographic Details
Main Authors: Giulio Metro, Andrea De Giglio, Biagio Ricciuti, Marco Siringo, Daniele Marinelli, Alain Gelibter, Federica Pecci, Rossana Berardi, Luca Cantini, Alessandro Di Federico, Elisa Andrini, Mirta Mosca, Giuseppe Lamberti, Marta Brambilla, Giannis Mountzios
Format: Article
Language:English
Published: BioExcel Publishing Ltd 2022-07-01
Series:Drugs in Context
Subjects:
amivantamab
egfr exon 20 insertion mutations
her2 mutation
mobocertinib
non-small-cell lung cancer
poziotinib
trastuzumab deruxtecan
Online Access:https://www.drugsincontext.com/advanced-non-small-cell-lung-cancer-how-to-manage-egfr-and-her2-exon-20-insertion-mutation-positive-disease

Internet

https://www.drugsincontext.com/advanced-non-small-cell-lung-cancer-how-to-manage-egfr-and-her2-exon-20-insertion-mutation-positive-disease

Similar Items